✦ LIBER ✦

Pegylated liposomal doxorubicin as a single agent or as combination therapy with carboplatin in patients with recurrent or refractory epithelial ovarian cancer

✍ Scribed by Keng Shen; Beihua Kong; Yunong Gao; Lingying Wu; Ziting Li; Yile Chen; Mengda Li; Yongliang Gao; Ding Ma; Zhilan Peng

Book ID: 107513258
Publisher: Springer-Verlag
Year: 2009
Weight: 360 KB
Volume: 6
Category: Article
ISSN: 1674-5361
DOI: 10.1007/s11805-009-0387-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated Liposomal Doxorubicin and Cycl

Pegylated Liposomal Doxorubicin and Cyclophosphamide as First-Line Therapy for Patients with Metastatic or Recurrent Breast Cancer

✍ Beth Overmoyer; Paula Silverman; Larry W. Holder; Debasish Tripathy; I. Craig He 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 493 KB

CA-125 response in patients with recurre

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

✍ Gabrielle Gossner; Robert L. Coleman; David G. Mutch; Neil S. Horowitz; Janet S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Phase 3 randomised study of canfosfamide

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

✍ I. Vergote; N. Finkler; J. del Campo; A. Lohr; J. Hunter; D. Matei; J. Kavanagh; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 317 KB

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

AMG 386 combined with either pegylated l

AMG 386 combined with either pegylated liposomal doxorubicin or topotecan in patients with advanced ovarian cancer: Results from a phase Ib study

✍ R. Wenham; R. Schilder; C. Pippitt; S. Wong; S. Ananda; S. Scudder; R. Melara; N 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB